Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970838 | 0.81 | ESR2 (0.46) | ESR2S1PR1S1PR3NR1H2KCNH2 | |
| SCHEMBL25574615 | 0.80 | ESR2 (0.58) | ESR2NR1H2USP30GPR119HDAC4 | |
| SCHEMBL19746839 | 0.80 | HDAC4 (0.64) | ESR2NR1H2HDAC4 | |
| SCHEMBL15971020 | 0.79 | NR1H2 (0.47) | ESR2S1PR1S1PR3NR1H2KCNH2 | |
| SCHEMBL2123001 | 0.78 | S1PR1 (0.64) | ESR2S1PR1S1PR5S1PR3KCNH2 | |
| SCHEMBL4750138 | 0.77 | S1PR1 (0.56) | ESR2S1PR1S1PR3USP30HDAC4 | |
| Trifluoroacetic Acid SCHEMBL1870072 | 0.77 | S1PR1 (0.61) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL13765620 | 0.77 | S1PR1 (0.49) | ESR2S1PR1S1PR3NR1H2KCNH2 | |
| SCHEMBL2989163 | 0.77 | S1PR1 (0.60) | S1PR1S1PR3KCNH2 | |
| SCHEMBL4565400 | 0.76 | GPR119 (0.59) | ESR2NR1H2GPR119HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | ESR2 355/4885S1PR1 1/4885S1PR4 6/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | ESR2 376/4885S1PR1 1/4885S1PR4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.